KRAS is a prevalent oncogenic mutation in NSCLC1

KRAS G12C is the most common KRAS mutation in NSCLC1,2



    Prevalence of oncogenic mutations in lung adenocarcinoma1,4    

Prevalence of oncogenic mutations in lung adenocarcinomas Prevalence of oncogenic mutations in lung adenocarcinomas

Biomarker identification at diagnosis can help improve patient management1,5-7

NSCLC treatments and targeted therapies NSCLC treatments and targeted therapies

  • Clinical guidelines recommend biomarker testing in patients diagnosed with advanced NSCLC8-11
  • Because KRAS mutations do not usually overlap with EGFR, ALK, and ROS1 mutations, patients with KRAS mutations are unlikely to benefit from further biomarker testing12

KRAS is among important emerging biomarkers that should be part of testing workflows*

*Other emerging biomarkers include RET, MET, and HER2.10,13

ALK, anaplastic lymphoma kinase; BRAF, proto-oncogene B-Raf; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma; MET, mesenchymal-to-epithelial transition; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; NTRK, neurotrophic tyrosine receptor kinase; NTRK1, neurotrophic tyrosine receptor kinase 1; PD-L1, programmed cell death ligand 1; PIK3CA, phosphoinositide 3-kinase, catalytic, alpha polypeptide; RET, rearranged during transfection; ROS1, c-ros oncogene 1.

References: 1. Pakkala S, et al. JCI Insight. 2018;3:e120858. 2. Arbour KC, et al. Clin Cancer Res. 2018;24:334-340. 3. American Cancer Society. Key Statistics for Lung Cancer. Accessed January 31, 2020. 4. Biernacka A, et al. Cancer Genet. 2016;209:195-198. 5. Zhang C, et al. J Hematol Oncol. 2019;12:45. 6. Nagasaka M, et al. Cancer Treatment Rev. 2020;84:101974. 7. Kim ES, et al. J Thorac Oncol. 2019;14:338-342. 8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v.2.2020. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed January 23, 2020. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 9. Lindeman NI, et al. J Thorac Oncol. 2018;13:323-358. 10. Kalemkerian GP, et al. J Clin Oncol. 2018;36:911-919. 11. Planchard D, et al. Ann Oncol. 2018;29(suppl 4):iv192-iv237. 12. Ahmadzada T, et al. J Clin Med. 2018;7:153. 13. Lindeman NI, et al. Arch Pathol Lab Med. 2018;142:321-346.